Diet-Derived Antioxidants: The Special Case of Ergothioneine.
Barry Halliwell, Richard M Y Tang, Irwin K Cheah
https://pubmed.ncbi.nlm.nih.gov/36623925Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID06487546
Repletion of Ergothioneine in Patients With Kidney Failure
Led by Stanford University · Updated on 2026-04-01
28
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to learn how well a daily ergothioneine supplement replenishes ergothioneine levels in the blood of people with kidney failure who are undergoing dialysis. Dialysis removes harmful chemicals but can also reduce valuable chemicals like ergothioneine, which comes from the diet and is usually low in these patients. The study is led by Stanford University and focuses on people with end-stage renal disease (ESRD). Participants in this randomized, triple-blinded study will receive either a daily ergothioneine capsule (ranging from 5 mg to 25 mg) or a matching placebo for up to 12 weeks. The study compares the effects of the supplement versus placebo on blood levels of ergothioneine during and after treatment. During the study, researchers will measure ergothioneine levels in red blood cells and plasma at multiple time points: weeks 1, 2, 4, 8, and 12 while taking the supplement or placebo, and weeks 16 and 20 after stopping treatment. Participants will be monitored for changes in these levels to understand how well the supplement replenishes ergothioneine. The total participation includes both the supplementation period and follow-up after stopping the treatment.
CONDITIONS
Brief Title
Repletion of Ergothioneine in Patients With Kidney Failure
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with kidney failure and currently receiving hemodialysis or peritoneal dialysis
You will not qualify if you...
- Received a blood transfusion within the past 90 days
- Currently taking supplements that contain ergothioneine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 12 weeks
Participants take ergothioneine or placebo capsules daily for up to 12 weeks.
Visits at weeks 1, 2, 4, 8, and 12 for assessments
Follow-up
Duration - 8 weeks after treatment ends
Participants are monitored after stopping ergothioneine or placebo to assess lasting effects.
Visits at weeks 16 and 20
Trial Site Locations
Total: 1 location
1
Veterans Affairs Palo Alto
Palo Alto, California, United States, 94304
Actively Recruiting
Loading map...
Research Team
T
Tammy Sirich, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Ergothioneine and its congeners: anti-ageing mechanisms and pharmacophore biosynthesis.
Li Chen, Liping Zhang, Xujun Ye...
https://pubmed.ncbi.nlm.nih.gov/37561026